Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.

about

Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis?

P2860

Q45882492-386F8E0E-D25A-40C7-8DE3-463B6074367C

P2860

Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.

Item

http://www.wikidata.org/entity/Q44778300

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Low daily dosage of interferon ...... A randomized-controlled study.

@en

Low daily dosage of interferon ...... A randomized-controlled study.

@nl

type

Item

label

Low daily dosage of interferon ...... A randomized-controlled study.

@en

Low daily dosage of interferon ...... A randomized-controlled study.

@nl

prefLabel

Low daily dosage of interferon ...... A randomized-controlled study.

@en

Low daily dosage of interferon ...... A randomized-controlled study.

@nl

P1476

Low daily dosage of interferon ...... A randomized-controlled study.

@en

P2093

A Perrella

http://www.w3.org/2001/XMLSchema#string

G Tarantino

http://www.w3.org/2001/XMLSchema#string

O Perrella

http://www.w3.org/2001/XMLSchema#string

P Conca

http://www.w3.org/2001/XMLSchema#string

P Ragucci

http://www.w3.org/2001/XMLSchema#string

P Sorrentino

http://www.w3.org/2001/XMLSchema#string

P2860

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.

Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response.

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.

P304

413-419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1478-3231.2003.00871.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14986815

http://www.w3.org/2001/XMLSchema#string

Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.

about

P2860

P2860

Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698